Displaying drugs 276 - 300 of 7378 in total
Nafcillin
A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 Enzyme Inducers ... Cytochrome P-450 CYP3A4 Inducers (moderate) …
Daprodustat
Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK.[A254167,A254162] Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Raloxifene
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM....
Approved
Investigational
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors …
Pretomanid
Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Fezolinetant
Vasomotor symptoms (VMS), more colloquially known as hot flashes or night sweats, are some of the most common symptoms in menopause. With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek treatments for menopausal issues.[A259591,A259596] Although mostly considered a nuisance, vasomotor symptoms...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2C19 Substrates ... Cytochrome P-450 CYP2C9 Substrates …
Griseofulvin
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
Approved
Investigational
Vet approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 Enzyme Inducers ... Cytochrome P-450 CYP1A2 Inducers (strength unknown) …
Clonazepam
A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796]
Since being...
Approved
Illicit
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2E1 Inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 Enzyme Inhibitors …
Lesinurad
Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 Enzyme Inducers …
Olanzapine
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by...
Approved
Investigational
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Meclizine
Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular system diseases. It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects. Commonly marketed under the brand name Antivert in...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2D6 Substrates …
Acetylcysteine
Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose.[L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.[A228158,A228163,A228168]
Acetylcysteine was granted FDA approval on 14 September 1963.
Approved
Investigational
Flunisolide
Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 Enzyme Inducers …
Vinorelbine
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
It is a third-generation vinca alkaloid. The introduction...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 Enzyme Inhibitors …
Desipramine
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Flunarizine
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2A6 Substrates ... Cytochrome P-450 CYP2C9 Substrates …
Hydroxyprogesterone caproate
Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. Food and Drug...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C19 Inducers ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 Enzyme Inducers ... Cytochrome P-450 CYP3A4 Substrates …
Vernakalant
Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP2D6 Substrates ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Trofinetide
Trofinetide is a novel synthetic analog of glypromate, also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (weak) …
Larotrectinib
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and...
Approved
Investigational
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Lovastatin
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of Aspergillus terreus. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP2C19 Substrates …
Remoxipride
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2D6 Substrates ... Cytochrome P-450 Enzyme Inhibitors …
Rupatadine
Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C19 Substrates ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2D6 Substrates …
Bexagliflozin
Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor.[A256408,A256413,L44758] Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is...
Approved
Investigational
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2D6 Substrates …
Remdesivir
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase...
Approved
Investigational
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP3A Substrates …
Glimepiride
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C9 Substrates …
Displaying drugs 276 - 300 of 7378 in total